302 related articles for article (PubMed ID: 7606729)
1. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
2. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
Yue W; Zhou D; Chen S; Brodie A
Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
[TBL] [Abstract][Full Text] [Related]
3. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
4. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
6. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
7. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie A; Jelovac D; Long BJ
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
[TBL] [Abstract][Full Text] [Related]
8. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
9. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
12. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Wing LY; Garrett WM; Brodie AM
Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
[TBL] [Abstract][Full Text] [Related]
13. Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione.
Wing LY; Hammond JO; Brodie AM
Endocrinology; 1988 Jun; 122(6):2418-27. PubMed ID: 3131115
[TBL] [Abstract][Full Text] [Related]
14. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
15. Differential response of an ovarian-responsive mouse mammary tumor to androgenic and estrogenic agents.
Matsuzawa A; Ikeda Y
Cancer Res; 1983 Aug; 43(8):3680-6. PubMed ID: 6861137
[TBL] [Abstract][Full Text] [Related]
16. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
Chen J; Hui E; Ip T; Thompson LU
Clin Cancer Res; 2004 Nov; 10(22):7703-11. PubMed ID: 15570004
[TBL] [Abstract][Full Text] [Related]
17. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
18. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
[TBL] [Abstract][Full Text] [Related]
19. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
